STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.
Luo T, Masson K, Jaffe JD, Silkworth W, Ross NT, Scherer CA, Scholl C, Fröhling S, Carr SA, Stern AM, Schreiber SL, Golub TR. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2860-5.